Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Appili Therapeutics Inc.
  6. News
  7. Summary
    APLI   CA03783R1073

APPILI THERAPEUTICS INC.

(APLI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about APPILI THERAPEUTICS INC.
2021Appili Therapeutics - Press Release Correction
AQ
2021Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners
AQ
2021Appili Therapeutics Loses 4% as Revises Funding Agreement with The Lind Partners
MT
2021Appili Therapeutics Revises Funding Agreement with The Lind Partners
MT
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
AQ
2021Appili Details "Positive" One Year Challenge Results from Preclinical Study Evaluating ..
MT
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
BU
2021Appili Therapeutics Inc. Announces Positive One Year Challenge Results from Preclinical..
CI
2021Appili Therapeutics Inc. Announces Resignation of Josef Vejvoda from the Board of Direc..
CI
2021Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan..
AQ
2021Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months..
CI
2021Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fis..
BU
2021Appili Therapeutics Inc. Announces Executive Changes
CI
2021IIROC Trade Resumption - APLI
AQ
2021Appili Therapeutics Says Phase 3 PRESECO Clinical Trial Did Not Meet Primary Endpoint
MT
More most relevant news
All news about APPILI THERAPEUTICS INC.
2021Appili Therapeutics - Press Release Correction
AQ
2021Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners
AQ
2021Appili Therapeutics Loses 4% as Revises Funding Agreement with The Lind Partners
MT
2021Appili Therapeutics Revises Funding Agreement with The Lind Partners
MT
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
AQ
2021Appili Details "Positive" One Year Challenge Results from Preclinical Study Evaluating ..
MT
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
BU
2021Appili Therapeutics Inc. Announces Positive One Year Challenge Results from Preclinical..
CI
2021Appili Therapeutics Inc. Announces Resignation of Josef Vejvoda from the Board of Direc..
CI
2021Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan..
AQ
More news
News in other languages on APPILI THERAPEUTICS INC.
2021Appili Therapeutics perd 4 % après révision de l'accord de financement avec The Lind Pa..
2021Appili Therapeutics propose un placement d'actions sur le marché du jour au lendemain -..
2021Appili Therapeutics augmente de 1% après avoir obtenu un million de dollars de FUJIFILM..
2021Appili Therapeutics en hausse de 5 % après la fin du recrutement des patients de la sou..
2021Appili Therapeutics en hausse de 2,9 % après avoir annoncé la conclusion d'un accord de..
2021MISE À JOUR : Appili Therapeutics perd 1,4 % et creuse sa perte nette au premier trimestre..
2021Appili Therapeutics creuse sa perte nette au premier trimestre fiscal
2021Appili Therapeutics annonce ses résultats financiers et opérationnels pour l'exercice 2..
2021Appili Therapeutics étend au Mexique et au Brésil l'essai clinique PRESECO sur le trait..
2021Appili Therapeutics fait le point sur l'essai de phase 3 évaluant l'antiviral oral Favi..
More news
Press releases
2021Appili Therapeutics - Press Release Correction
AQ
2021Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners
AQ
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
AQ
2021Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Stud..
BU
2021Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan..
AQ
More press releases
Upcoming event on APPILI THERAPEUTICS INC.